

Election of chairman of the Meeting (item 2)

The Nomination Committee of Swedish Orphan Biovitrum AB (publ), which consists of Håkan Björklund (chairman of the Board of Directors), Petra Hedengran, chairman (Investor AB), Lennart Francke (Swedbank Robur Fonder AB) and Thomas Ehlin (The Fourth Swedish National Pension Fund (AP4)), proposes that Eva Hägg from Mannheimer Swartling Advokatbyrå is elected chairman of the Meeting.

Fees for the members of the Board of Directors and the auditor (item 13)

The Nomination Committee proposes the following:

- that fees to be paid to the Board of Directors should be SEK 1,675,000 (1,575,000) to the chairman of the Board of Directors, SEK 900,000 (–) to the deputy chairman of the Board of Directors and SEK 550,000 (515,000) to each of the other members of the Board of Directors elected by the Annual General Meeting, that fees for work in the Audit Committee should be SEK 185,000 (175,000) to the chairman and SEK 110,00 (105,000) to each other member of such committee, that fees for work in the Compensation & Benefits Committee should be SEK 120,000 (115,000) to the chairman and SEK 70,000 (65,000) to each other member of such committee and that fees for work in the Science Committee should be SEK 120,000 (115,000) to the chairman and SEK 70,000 (65,000) to each other member of such committee,
- that, in addition to the fees proposed above, for each physical meeting of the Board of Directors held in Sweden, a meeting fee of SEK 20,000 (10,000) is paid to the members of the Board of Directors that reside in Europe outside the Nordic countries and a meeting fee of USD 3,500 (3,000) is paid to the members of the Board of Directors that reside outside Europe, and
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice.

The number of members of the Board of Directors, deputy members, auditors and deputy auditors (item 14)

The Nomination Committee proposes the following:

- that seven ordinary members of the Board of Directors without deputies should be appointed, and
- that one auditor without any deputy auditor should be appointed.

Election of the chairman, the members of the Board of Directors and the auditor (item 15)

The Nomination Committee proposes the following:

- that Håkan Björklund, Annette Clancy, Matthew Gantz, Helena Saxon, Staffan Schüberg and Filippa Stenberg should be re-elected as ordinary members of the Board of Directors, that Bo Jesper Hansen should be elected as new ordinary member of the Board of Directors and that Håkan Björklund should be re-elected as chairman of the Board of Directors, and

- that Ernst & Young AB should be re-elected as auditor of the company until the end of the Annual General Meeting 2023, in accordance with the Audit Committee's recommendation.

Bo Jesper Hansen

Bo Jesper Hansen (born 1958) has a MD-PhD from the University of Copenhagen.

Bo Jesper is a member of the Board of Directors of Reapplix A/S, Laborie Inc. and Orphazyme A/S. He is also Senior Advisor at EQT and Global Healthcare Advisor at Goldman Sachs, as well as Venture partner at Wellington Partners, Senior Business Advisor at HBM Ventures and Advisor at Aescap Venture Fund. He has a long history within the Sobi group and, among other things, established Orphan Denmark A/S and Orphan Norway AS. Bo Jesper was also CEO of Swedish Orphan International AB 1998–2010, co-founder of Swedish Orphan Biovitrum AB (publ) and executive chairman of the Board of Directors of Swedish Orphan Biovitrum AB (publ) 2010–2016. He has previously served on the Board of Directors of a number of listed companies and also has extensive experience from several executive positions within research and development in the international pharmaceutical industry.

The Nomination Committee recommends the elected board members to build their own holdings of shares in the company

Similar to previous years, the Nomination Committee recommends the Board of Directors of Swedish Orphan Biovitrum AB (publ) to establish a shareholding policy pursuant to which the members of the Board of Directors, who do not already have such holding, are expected to, over a five year period, acquire an ownership in Swedish Orphan Biovitrum AB (publ) shares with a market value which is expected to correspond to at least one year board remuneration, before taxes, excluding remuneration for committee work.